menu
    • menu
    [{"orgOrder":0,"company":"Civica Rx","sponsor":"Kaiser Permanente Washington Health Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Civica Rx \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Civica Rx \/ Civica Rx"},{"orgOrder":0,"company":"Civica Rx","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Pantoprazole Sodium","moa":"H\/K ATPase","graph1":"Gastroenterology","graph2":"Approved","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Civica Rx \/ Civica Rx","highestDevelopmentStatusID":"12","companyTruncated":"Civica Rx \/ Civica Rx"},{"orgOrder":0,"company":"Civica Rx","sponsor":"GeneSys Biologics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Civica Rx \/ GeneSys Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Civica Rx \/ GeneSys Biologics"},{"orgOrder":0,"company":"Civica Rx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","graph1":"Oncology","graph2":"Approved","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Civica Rx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Civica Rx \/ Not Applicable"},{"orgOrder":0,"company":"Civica Rx","sponsor":"Ypsomed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Partnership","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Civica Rx \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Civica Rx \/ Civica Rx"},{"orgOrder":0,"company":"Civica Rx","sponsor":"CalRx Biosimilar Insulin Initiative","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Partnership","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Civica Rx","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Civica Rx \/ CalRx Biosimilar Insulin Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Civica Rx \/ CalRx Biosimilar Insulin Initiative"}]

    Find Clinical Drug Pipeline Developments & Deals by Civica Rx

    Menu

    Civica Rx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : CalRx Biosimilar Insulin Initiative

                            Deal Size : $50.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            California Selects Civica Rx as Its Insulin Manufacturing Partner

                            Details : Under the agreement, Californians with diabetes will have access to Civica’s low-cost insulins via the CalRx Biosimilar Insulin Initiative. Civica will produce three insulins, glargine, lispro and aspart, available both in vials and prefilled pens unde...

                            Brand Name : Undislcosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 18, 2023

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : CalRx Biosimilar Insulin Initiative

                            Deal Size : $50.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : Ypsomed

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

                            Details : Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and to ensure redundancy of supply, Ypsomed will provide injector dosing pens from their manufacturing...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 31, 2023

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : Ypsomed

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CivicaScript Announces Launch of its First Product, Creating Significant Patient Savings

                            Details : Abiraterone acetate 250 mg is indicated in combination with prednisone for the treatment of people with metastatic castration-resistant prostate cancer (CRPC) and those with metastatic high-risk castration-sensitive prostate cancer (CSPC).

                            Brand Name : Abiraterone Acetate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : GeneSys Biologics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership

                            Details : Civica will produce three insulins – glargine, lispro and aspart (biologics corresponding to, and interchangeable with, Lantus, Humalog and Novolog respectively) – each of which will be available both in vials and prefilled pens.

                            Brand Name : Insulin Glargine-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 03, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : GeneSys Biologics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pantoprazole Sodium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Recipient : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sandoz Ships First Medicine in Collaboration with Civica Rx to Supply Us Hospitals

                            Details : Sandoz has shipped pantoprazole sodium for injection, 40 mg to Civica Rx to supply the hospitals it serves as part of a multiyear collaboration to help reduce supply shortages, with several other medicines on the way before the end of the year.

                            Brand Name : Pantoprazole Sodium-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 02, 2020

                            Lead Product(s) : Pantoprazole Sodium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Recipient : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Civica Rx

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Kaiser Permanente Washington Health Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kaiser Permanente Joins Forces with Civica Rx to Improve Availability and Affordability of Essential Generic M...

                            Details : Kaiser Permanente to join as a governing member with the goal of helping to secure supplies of essential generic medications during COVID-19 and beyond.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Kaiser Permanente Washington Health Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth